NYSE:ADCT

ADC Therapeutics - ADCT News Today

$5.05

+0.33 (+6.99%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $4.64
▼
$5.07
50-Day Range: $2.87
▼
$5.20
52-Week Range: $2.69
▼
$17.89

Volume: 346,779 shs
Average Volume: 691,223 shs
Market Capitalization: $387.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

Institutional Ownership

Get ADC Therapeutics News Delivered to You Automatically

ADCT Media Mentions By Week

ADCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADCT
News Sentiment
▼
0.00

0.70
▲
Average
Medical
News Sentiment

ADCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADCT Articles
This Week
▼
8

2
▲
ADCT Articles
Average Week

Source

Source	Headline
	ADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Moderate Buy" from Brokerages marketbeat.com - January 25 at 5:09 AM
	ADC Therapeutics SA (NYSE:ADCT) Receives $11.50 Average Target Price from Analysts americanbankingnews.com - January 28 at 1:44 AM
	Morgan Stanley Trims ADC Therapeutics (NYSE:ADCT) Target Price to $5.00 americanbankingnews.com - January 27 at 5:50 AM
	ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages americanbankingnews.com - January 25 at 5:14 AM
	Morgan Stanley Reaffirms Their Hold Rating on ADC Therapeutics (ADCT) markets.businessinsider.com - January 24 at 1:50 PM
	The Latest Analyst Ratings for ADC Therapeutics msn.com - January 24 at 1:50 PM
	Can ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta? markets.businessinsider.com - January 18 at 8:22 AM
	Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet finance.yahoo.com - January 16 at 1:37 PM
	ADC Therapeutics Uptrend Continues nasdaq.com - January 14 at 3:22 PM
	AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet) seekingalpha.com - January 6 at 2:26 PM
	PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics finanznachrichten.de - January 5 at 8:56 AM
	IntoCell enters development and license option agreement with ADC Therapeutics msn.com - January 5 at 8:56 AM
	4 Analysts Have This to Say About ADC Therapeutics msn.com - January 4 at 9:17 AM
	ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 4 at 9:17 AM
	ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer finance.yahoo.com - January 3 at 6:48 PM
	ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma finance.yahoo.com - December 21 at 10:15 AM
	ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer finance.yahoo.com - December 19 at 12:08 PM
	FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS finance.yahoo.com - December 12 at 1:03 PM
	ADC Therapeutics: Running Through A Stretch Of Bad Luck seekingalpha.com - November 30 at 10:01 AM
	Biocytogen Enters into Antibody Agreement with ADC Therapeutics nz.finance.yahoo.com - November 27 at 7:15 PM
	Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022 msn.com - November 9 at 11:24 AM
	ADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcript seekingalpha.com - November 9 at 1:10 AM
	ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting finance.yahoo.com - November 3 at 11:09 AM
	IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma finance.yahoo.com - November 2 at 7:43 PM
	ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer finance.yahoo.com - November 1 at 8:29 AM
	ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022 finance.yahoo.com - October 31 at 10:18 AM
	Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT) finance.yahoo.com - October 12 at 1:39 PM
	Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround finance.yahoo.com - October 11 at 12:37 PM
	ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) finance.yahoo.com - September 21 at 7:16 PM
	ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma finance.yahoo.com - September 16 at 8:59 AM
	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ADC Therapeutics SA (ADCT) Investigation benzinga.com - September 15 at 5:55 PM
	INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm apnews.com - September 14 at 4:52 PM
	INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm apnews.com - September 14 at 4:52 PM
	INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm apnews.com - September 14 at 1:15 AM
	Where ADC Therapeutics Stands With Analysts msn.com - September 9 at 4:44 PM
	Expert Ratings for ADC Therapeutics markets.businessinsider.com - September 9 at 4:44 PM
	ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference finance.yahoo.com - September 6 at 10:11 AM
	ADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript finance.yahoo.com - August 10 at 3:17 AM
	ADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 9 at 5:16 PM
	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates finance.yahoo.com - August 9 at 5:16 PM
	ADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates finanznachrichten.de - August 9 at 8:58 AM
	ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates finance.yahoo.com - August 9 at 8:58 AM
	Earnings Outlook For ADC Therapeutics msn.com - August 8 at 5:57 PM
	Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised) finance.yahoo.com - August 5 at 8:11 AM
	ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022 finance.yahoo.com - August 2 at 7:53 AM
	Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline finance.yahoo.com - July 27 at 2:27 PM
	ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors finance.yahoo.com - July 27 at 9:26 AM
	ADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? finance.yahoo.com - July 26 at 1:25 PM
	Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead? finance.yahoo.com - July 25 at 5:22 PM
	ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma finance.yahoo.com - July 20 at 10:12 AM
	Analyst Forecasts For ADC Therapeutics SA (NYSE:ADCT) Are Surging Higher finance.yahoo.com - July 16 at 8:49 AM

Get ADC Therapeutics News Delivered to You Automatically

This page (NYSE:ADCT) was last updated on 1/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ADC Therapeutics - ADCT News Today

ADCT Media Mentions By Week

ADCT Media Sentiment

ADCT News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info